Fusion Pharmaceuticals (NASDAQ:FUSN) just reported results for the first quarter of 2024.
- Fusion Pharmaceuticals reported earnings per share of -40 cents. This was below the analyst estimate for EPS of -37 cents.
- The company did not report any revenue for the quarter.